贝伐珠单抗联合化疗对晚期结直肠癌血清肿瘤标志物及血清TGF-β1、Smad-3、Smad-7的影响  

Effects of bevacizumab plus chemotherapy on serum tumor markers and serum levels of transforming growth factor-β1,Smad-3 and Smad-7 in advanced colorectal cancer

作　　者：顾晶晶 陈萍[2] 高婕[2] 赵东坤[2] 王克山 柳善刚 邢爱敏[3] GU Jingjing;CHEN Ping;Gao Jie;ZHAO Dongkun;WANG Keshan;LIU Shangang;XING Aimin(Department of Pharmacy,Fourth Municipal People's Hospital,Shandong Zibo 255067,China;Department of Pharmacy,Central Municipal Hospital,Shandong Zibo 255000,China;Editorial Office of Progress in Pharmaceutical Science,China Pharmaceutical University,Jiangsu Nanjing 210009,China)

机构地区：[1]淄博市第四人民医院药剂科,山东淄博255067 [2]淄博市中心医院药剂科,山东淄博255000 [3]中国药科大学《药学进展》编辑部,江苏南京210009

出　　处：《中国医院药学杂志》2024年第24期2904-2908,共5页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨贝伐珠单抗联合化疗对晚期结直肠癌(colorectal cancer,CRC)患者血清肿瘤标志物及血清转化生长因子β1(transforming growth factor-beta 1,TGF-β1)、Smad-3、Smad-7的影响。方法:2020年11月至2021年11月期间于淄博市第四人民医院接受诊治且随访至2023年12月的晚期CRC患者62例作为研究对象,按照随机数字表法分为对照组(FOLFOX6化疗方案)与观察组(贝伐珠单抗联合FOLFOX6化疗方案),各31例,2组均以14 d为1个周期,连续治疗4个周期,疗程结束后,所有患者随访2年。对比2组临床近期和远期疗效,治疗前和治疗4个周期的血清肿瘤标志物水平和血清TGF-β1、Smad-3、Smad-7水平及不良反应。结果:治疗4个周期后,观察组的客观缓解率、疾病控制率显著高于对照组(P<0.05);随访2年,观察组无进展生存期、总生存期长于对照组,复发率、死亡率则低于对照组(P<0.05)。治疗4个周期后,观察组血清糖类抗原125、细胞角质蛋白19片段抗原21-1、癌胚抗原、TGF-β1、Smad-3水平低于对照组,而Smad-7水平高于对照组(P<0.05)。观察组不良反应总发生率与对照组相比,差异无统计学意义(χ^(2)=1.620,P=0.203)。结论:贝伐珠单抗联合FOLFOX6方案化疗治疗晚期CRC有利于调节血清肿瘤标志物及TGF-β1、Smad-3、Smad-7水平。OBJECTIVE To explore the effects of bevacizumab plus chemotherapy on serum tumor markers and serum levels of transforming growth factor-beta 1(TGF-β1),Smad-3 and Smad-7 in advanced colorectal cancer(CRC).METHODS A total of 62 CRC patients hospitalized from November 2020 to November 2021 at Fourth Municipal People's Hospital,and followed up until December 2023 were randomized into two groups of control(receiving FOLFOX6 chemotherapy)and observation(receiving bevacizumab plus FOLFOX6 chemotherapy)(n=31 each).Fourteen days were counted as one cycle and treatment lasted for four cycles in two groups.After the end of treatment course,all patients were followed up for 2 years.Recent and longterm clinical efficacy,serum levels of tumor markers,TGF-β1,Smad-3,Smad-7,as well as adverse reactions before and after treatment for four cycles were compared between two groups.RESULTS After 4 cycles of treatment,objective remission rate and disease control rate of observation group were significantly higher than those of control group(P<0.05).After 2-year followups,progression-free survival(PFS)and overall survival(OS)of observation group were longer than those of control group while recurrence rate and mortality were lower than those of control group(P<0.05).After 4 cycles of treatment,serum levels of carbohydrate antigen 125,cytokeratin 19 fragment antigen 21-1,carcinoembryonic antigen,TGF-β1 and Smad-3 were lower in observation group than those in control group while the level of Smad-7 was higher than that in control group(P<0.05).No significant inter-group difference existed in overall incidence of adverse reactions(χ^(2)=1.620,P=0.203).CONCLUSION Bevacizumab plus FOLFOX6 chemotherapy for advanced CRC may facilitate regulating serum levels of tumor markers,TGF-β1,Smad-3 and Smad-7.

关 键 词：贝伐珠单抗 化疗 晚期结直肠癌 

分 类 号：R969.4[医药卫生—药理学]